Editas Medicine

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell EDIT and other ETFs, options, and stocks.

About EDIT

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). 

CEO
Gilmore O’Neill
CEOGilmore O’Neill
Employees
246
Employees246
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2013
Founded2013
Employees
246
Employees246

EDIT Key Statistics

Market cap
137.70M
Market cap137.70M
Price-Earnings ratio
-0.54
Price-Earnings ratio-0.54
Dividend yield
Dividend yield
Average volume
1.65M
Average volume1.65M
High today
$1.65
High today$1.65
Low today
$1.45
Low today$1.45
Open price
$1.52
Open price$1.52
Volume
1.13M
Volume1.13M
52 Week high
$6.69
52 Week high$6.69
52 Week low
$0.9101
52 Week low$0.9101

EDIT News

Simply Wall St 4d
Recent uptick might appease Editas Medicine, Inc. institutional owners after losing 71% over the past year

Advertisement Key Insights Significantly high institutional ownership implies Editas Medicine's stock price is sensitive to their trading actions 50% of the...

Recent uptick might appease Editas Medicine, Inc. institutional owners after losing 71% over the past year
TipRanks 5d
Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Pipeline and key...

Analyst ratings

47%

of 15 ratings
Buy
40%
Hold
46.7%
Sell
13.3%

People also own

Based on the portfolios of people who own EDIT. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.